# BPC-157 Dosage: How Doses Are Expressed in the Research | Safe BPC-157 > BPC-157 dosage in context: the per-kilogram animal-model figures used in the literature, the routes studied, the short half-life, and why none of it constitutes human dosing guidance. What the studies administered, to which species, by which route — and why per-kilogram animal figures are not a human protocol. ## A note before any numbers This page describes BPC-157 dosage as it appears in the research record. It is not dosing guidance, and there is no validated human dose, schedule, or duration. Nearly every figure in the literature is expressed per kilogram of an animal's body weight, in studies designed to probe mechanism — not to model how a person would use the compound. That distinction is the whole point of the page. Reading an animal's per-kilogram research dose as a human instruction is the single most common error in this space, and it is one this digest is built to avoid. Animal dosing is chosen to expose a biological effect cleanly; human dosing, where it is ever established, is chosen to balance benefit against risk in a regulated trial. BPC-157 has the former and not the latter. ## How BPC-157 Doses Are Expressed in the Literature How BPC-157 doses are expressed in the literature is almost always per body weight, in animals. Rodent studies commonly cluster around 10 microg/kg and 10 ng/kg, and some tendon work tested doses as low as 10 pg [1]. Gastric-ulcer cytoprotection was studied at 400 ng/kg and 800 ng/kg in rats [4]. These are animal-model figures chosen to map dose-response and mechanism, not human guidance. One feature of the BPC-157 literature is worth flagging: the active range spans many orders of magnitude. When a compound is reported to work at 10 microg/kg and also at 10 ng/kg and even 10 pg in some tendon work [1], that very flatness of the dose-response curve is itself an unusual finding — and one reason the field is studied so heavily and trusted so cautiously. A wide effective range in animals does not translate into a known effective dose in people. The human pilot data are minimal and use very different absolute amounts because they are whole-body infusions rather than per-kilogram animal doses: a two-person intravenous safety pilot used 10 mg then 20 mg by infusion, and an interstitial-cystitis pilot used 10 mg intravesically [11][13]. The gap between a microgram-per-kilogram rat dose and a milligram human infusion is exactly why the two literatures cannot be casually converted into each other. Allometric scaling — the math used to estimate a human dose from an animal one — is an approximation even for well-characterized drugs, and it has never been validated for BPC-157 against human outcomes. ## Routes studied The literature spans an unusually wide set of routes, which is part of what makes BPC-157 a research curiosity. In rodents the most common route is intraperitoneal injection, with intramuscular, intragastric/peroral, and local or intra-lesional delivery also studied [1][4][5]. The peripheral-nerve work, for instance, delivered the peptide intraperitoneally, intragastrically, or locally via nerve tubing within the same body of research [5]. The human pilots used intravenous infusion, intravesical instillation, and intra-articular injection [11][13]. Route matters for this molecule. The same gastric-ulcer study that anchors the cytoprotection literature found intramuscular delivery outperformed intragastric [4], a recurring theme that complicates the popular interest in oral use. The intramuscular bioavailability figures from the pharmacokinetic work — roughly 14-19% in rats and 45-51% in dogs [2] — also show how much route and even species change how much peptide actually reaches circulation. Route, dose, and species all move together in these studies, and none of the combinations has been validated as a human protocol. ## Half-life, stability, and what they imply The pharmacokinetic work reports a short window. In rats and dogs, the elimination half-life of the prototype peptide was less than 30 minutes, with linear pharmacokinetics and intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs [2]. A sub-30-minute half-life means the parent peptide does not linger; it is rapidly broken into fragments that enter normal amino-acid metabolism [2]. The "stable gastric pentadecapeptide" label refers to stability in gastric juice, which underlies interest in oral and peroral routes [4]. Despite that, formal human oral pharmacokinetics are not established, and storage or reconstitution practices described in research contexts are not validated clinical protocols. Stability in the stomach is not the same as a known human dose. ## Study durations and the human pilots Duration in the animal literature is a function of the model, not a recommended course. Tendon, gastric-ulcer, and nerve studies typically dose once daily across the days needed for the injury to heal in that model [1][4][5]; the figure that matters in those papers is the healing endpoint, not a calendar of human use. There is no animal study that establishes how long a person should use BPC-157, because that is not a question animal injury models can answer. The human side is thinner still. As of 2025 reviews, only three small human pilot studies exist — a 2-participant intravenous safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot [11][13]. One historical industrial development program (under the designations PL 14736 and PLD-116) reported the peptide was safe in early inflammatory-bowel-disease trials, but large, rigorous, controlled human efficacy trials are lacking [12]. None of this constitutes a validated human dose, schedule, or duration, and this site does not supply one. ## How long should I stay on BPC-157? No validated human duration exists. Published doses are per-kilogram animal-model figures, not human protocols [1][4], and there is no clinical guidance on length of use. The literature simply does not answer a question that would require human trials it has not run. --- A Material knowledge-panel reading of the BPC-157 record — each finding chipped ESTABLISHED, PRECLINICAL, or CAUTION against its source, the 503A status read first, and no clinic behind the panel and nothing here to dispense.